# EDGAR Filing Document

**Accession Number:** 0001533998
**File Stem:** 0001104659-26-059676
**Filing Date:** 2026-5
**Character Count:** 124162
**Document Hash:** 37f0001a6a017a700785935446ae48c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-059676.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001104659-26-059676

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 79

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DarioHealth Corp.
- **CENTRAL INDEX KEY:** 0001533998
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 452973162
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37704
- **FILM NUMBER:** 26970769

**BUSINESS ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 972-4-770-6377

**MAIL ADDRESS:**
- **STREET 1:** 322 W 57TH ST. #33B
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LabStyle Innovations Corp.
- **DATE OF NAME CHANGE:** 20111101

?xml version='1.0' encoding='ASCII'? DarioHealth Corp._March 31, 2026

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

---

| | |
|:---|:---|
| **☒** | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|  | **For the quarterly period ended March 31, 2026** |
| **☐** | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|  | **For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to** |

---

**Commission File No. 001-37704**

---

| |
|:---|
| **DarioHealth Corp.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **45-2973162** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **322 W. 57th St. #33B** |  |
| **New York, New York** | **10019** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

---

| |
|:---|
| **(972)-4770-4042** |
| (Registrant's telephone number, including area code) |

---

---

| |
|:---|
| **n/a** |
| (Former name, former address and former fiscal year, if changed since last report) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of exchange on which registered** |
| Common Stock, par value $0.0001 per share | DRIO | The Nasdaq Capital Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer ☐ Accelerated filer <br> ☒ Non-accelerated filer ☒ Smaller reporting company <br> ☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 12, 2026, the registrant had 7,312,398 shares of common stock outstanding.

When used in this quarterly report, the terms "Dario," "DarioHealth," "the Company," "we," "our," and "us" refer to DarioHealth Corp., a Delaware corporation and our subsidiary LabStyle Innovation Ltd., an Israeli company, PsyInnovations Inc., a Delaware corporation, Twill, Inc., a Delaware corporation, and DarioHealth India Services Pvt. Ltd., an Indian company. Dario is registered as a trademark in the United States, China, Canada, Hong Kong, Australia, Brazil, the EU, and is also registered as a WO (WIPO registration). "DarioHealth" is registered as a trademark in the United States, Israel, China, Canada, Australia, India, Japan, the EU, and as a WO.

[**Table of Contents**](#TOC)

------

[**Table of Contents**](#TOC)

#### DarioHealth Corp.

#### Quarterly Report on Form 10-Q

#### **TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| [Cautionary Note Regarding Forward-Looking Statements](#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA) | [Cautionary Note Regarding Forward-Looking Statements](#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA) | 4 |
| [**PART 1 - FINANCIAL INFORMATION**](#INTERIMCONSOLIDATEDFINANCIALSTATEMENTS_6) | [**PART 1 - FINANCIAL INFORMATION**](#INTERIMCONSOLIDATEDFINANCIALSTATEMENTS_6) |  |
| &nbsp;&nbsp;[Item 1.](#INTERIMCONSOLIDATEDFINANCIALSTATEMENTS_6) | [Condensed Consolidated Interim Financial Statements (unaudited)](#INTERIMCONSOLIDATEDFINANCIALSTATEMENTS_6) | F-1 |
|  | [Condensed Consolidated Interim Balance Sheets (Unaudited)](#CONSOLIDATEDBALANCESHEETS_768529) | F-2 – F-3 |
|  | [Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited)](#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOS) | F-4 |
|  | [Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited)](#stockholders_equity) | F- 5 – F-5 |
|  | [Condensed Consolidated Interim Statements of Cash Flows (Unaudited)](#CONSOLIDATEDINTERIMSTATEMENTOFCASHFLOW) | F-6  |
|  | [Notes to Condensed Consolidated Interim Financial Statements](#NOTE1GENERAL_494608) | F-7 – F-20 |
| &nbsp;&nbsp;[Item 2.](#Item2ManagementsDiscussionandAnalysisofF) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF) | 4 |
| &nbsp;&nbsp;[Item 4.](#Item4ControlsandProcedures_710243) | [Control and Procedures](#Item4ControlsandProcedures_710243) | 11 |
| [**PART II - OTHER INFORMATION**](#PARTIIOTHERINFORMATION_693715) | [**PART II - OTHER INFORMATION**](#PARTIIOTHERINFORMATION_693715) | 12 |
| &nbsp;&nbsp;[Item 1A.](#Item1ARiskFactors_910915) | [Risk Factors](#Item1ARiskFactors_910915) | 12 |
| &nbsp;&nbsp;[Item 6.](#Item6Exhibits_540964) | [Exhibits](#Item6Exhibits_540964) | 13 |
| [**SIGNATURES**](#SIGNATURES_648939) | [**SIGNATURES**](#SIGNATURES_648939) | 14 |

---

[**Table of Contents**](#TOC)

#### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere herein may address or relate to future events and expectations and as such constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

● our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise;

● our ability to meet the requirements of our existing debt facility;

● our product launches and market penetration plans;

● the execution of agreements with various providers for our solution;

● our ability to maintain our relationships with key partners;

● our ability to maintain or protect the validity of our U.S. and other patents and other intellectual property;

● our ability to retain key executive members;

● our ability to internally develop new inventions and intellectual property;

● that our financial position raises substantial doubt about our ability to continue as a going concern;

● the ability to consummate a potential sale, merger or strategic business combination;

● general market, political and economic conditions in the countries in which we operate, including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the attack by Hamas and other terrorist organizations in the Middle East and Israel's war against them;

● changes or developments in U.S. laws or policies, including changes in U.S. trade policies and tariffs;

● interpretations of current laws and the passages of future laws; and

● acceptance of our business model by investors.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2025 (filed on March 19, 2026) entitled "Risk Factors" as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES

#### CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

#### MARCH 31, 2026

#### UNAUDITED

#### INDEX

---

| | |
|:---|:---|
|  | **Page** |
| [**Condensed Consolidated Interim Balance Sheets**](#CONSOLIDATEDBALANCESHEETS_768529) | **F-2 – F-3** |
| [**Condensed Consolidated Interim Statements of Comprehensive Loss**](#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOS) | **F-4** |
| [**Condensed Consolidated Interim Statements of Changes in Stockholders' Equity**](#STATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY_) | **F-5 – F-5** |
| [**Condensed Consolidated Interim Statements of Cash Flows**](#CONSOLIDATEDINTERIMSTATEMENTOFCASHFLOW) | **F-6**  |
| [**Notes to Condensed Consolidated Interim Financial Statements**](#NOTE1GENERAL_494608) | **F-7 – F-20** |

---

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (UNAUDITED)**

**U.S. dollars in thousands**

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,** <br>**2025** |
| ASSETS |  |  |
| CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $14977 | $21803 |
| &nbsp;&nbsp;Short-term bank deposits | 5035 | 4214 |
| &nbsp;&nbsp;Short-term restricted bank deposits | 252 | 229 |
| &nbsp;&nbsp;Trade receivables, net | 2219 | 2144 |
| &nbsp;&nbsp;Inventories | 4172 | 4316 |
| &nbsp;&nbsp;Other accounts receivable and prepaid expenses | 2079 | 2361 |
| Total current assets | 28734 | 35067 |
| NON-CURRENT ASSETS: |  |  |
| &nbsp;&nbsp;Deposits  | 80 | 80 |
| &nbsp;&nbsp;Operating lease right of use assets | 607 | 717 |
| &nbsp;&nbsp;Long-term assets | 454 | 304 |
| &nbsp;&nbsp;Property and equipment, net | 511 | 549 |
| &nbsp;&nbsp;Intangible assets, net | 15468 | 15931 |
| &nbsp;&nbsp;Goodwill | 57427 | 57427 |
| Total non-current assets | 74547 | 75008 |
| Total assets | $103281 | $110075 |

---

The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements.

[**Table of Contents**](#TOC)

**CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,** <br>**2025** |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| CURRENT LIABILITIES: |  |  |
| &nbsp;&nbsp;Trade payables | $3468 | $2928 |
| &nbsp;&nbsp;Deferred revenues | 501 | 714 |
| &nbsp;&nbsp;Operating lease liabilities | 378 | 430 |
| &nbsp;&nbsp;Other accounts payable and accrued expenses | 5010 | 5251 |
| Total current liabilities | 9357 | 9323 |
| NON-CURRENT LIABILITIES |  |  |
| &nbsp;&nbsp;Operating lease liabilities  | 507 | 571 |
| &nbsp;&nbsp;Long-term loan | 30931 | 30747 |
| &nbsp;&nbsp;Warrant liability | 23 | 1466 |
| &nbsp;&nbsp;Other long-term liabilities | 83 | 46 |
| Total non-current liabilities | 31544 | 32830 |
| STOCKHOLDERS' EQUITY \*\* |  |  |
| &nbsp;&nbsp;Common stock of $0.0001 par value - authorized: 400,000,000 shares; issued and outstanding: 7,299,026 and 6,905,948 shares on March 31, 2026 and December 31, 2025, respectively  | 4 | 4 |
| &nbsp;&nbsp;Additional paid-in capital | 522703 | 519996 |
| &nbsp;&nbsp;Accumulated deficit | (460327) | (452078) |
| Total stockholders' equity | 62380 | 67922 |
| Total liabilities and stockholders' equity | $103281 | $110075 |

---

(\*\*) See note 1e regarding reverse share split.

The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements.

[**Table of Contents**](#TOC)

**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

---

| | | |
|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  |
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
| Revenues: |  |  |
| &nbsp;&nbsp;Services | $2826 | $4875 |
| &nbsp;&nbsp;Consumer hardware | 2758 | 1877 |
| Total revenues | 5584 | 6752 |
| Cost of revenues: |  |  |
| &nbsp;&nbsp;Services | 563 | 865 |
| &nbsp;&nbsp;Consumer hardware | 1644 | 1130 |
| &nbsp;&nbsp;Amortization of acquired intangible assets | 177 | 875 |
| Total cost of revenues | 2384 | 2870 |
| Gross profit | 3200 | 3882 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;Research and development | $2385 | $4108 |
| &nbsp;&nbsp;Sales and marketing | 4898 | 5873 |
| &nbsp;&nbsp;General and administrative | 3226 | 3310 |
| Total operating expenses | 10509 | 13291 |
| Operating loss | 7309 | 9409 |
| Interest expenses | 1149 |  |
| Other financial income, net | (266) | (204) |
| Total financial expenses (income), net | 883 | (204) |
| Loss before taxes | 8192 | 9205 |
| Income tax (benefit) | 57 | 22 |
| &nbsp;&nbsp;Net loss | $8249 | $9227 |
| &nbsp;&nbsp;Deemed dividend | $— | $4839 |
| &nbsp;&nbsp;Net loss attributable to common shareholders  | $8249 | $14066 |
| Net loss per share: |  |  |
| &nbsp;&nbsp;Basic and diluted loss per share of common stock | $1.25 | $2.87 |
| &nbsp;&nbsp;Weighted average number of common stock used in computing basic and diluted net loss per share\*\* | 6582297 | 2368516 |

---

(\*\*) See note 1e regarding reverse share split.

The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements.

[**Table of Contents**](#TOC)

#### CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
**(UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | | | |
| **Three Months Ended March 31, 2026** | **Number\*\*** | **Amount** | **Number** | **Amount** | **Additional**<br>**paid-in**<br>**capital** | <br>**Accumulated**<br>**deficit** | **Total**<br>**stockholders'**<br>**equity** |
| Balance as of December 31, 2025 | 6905948 | $4 |  | $— | $519996 | $(452078) | $67922 |
| Issuance of common stock related to lock up agreement | 204851 | \*)- |  |  |  |  |  |
| Exercise of pre-funded warrant to common stock | 186998 | \*)- |  |  | 1266 |  | 1266 |
| Stock-based compensation | 1229 | \*)- |  |  | 1441 |  | 1441 |
| Net loss |  |  |  |  |  | (8249) | (8249) |
| Balance as of March 31, 2026 | 7299026 | $4 |  | $— | $522703 | $(460327) | $62380 |
|  |  |  |  |  | **Additional** |  | **Total** |
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | **paid-in** | **Accumulated** | **stockholders'** |
| **Three Months Ended March 31, 2025** | **Number\*\*** | **Amount** | **Number** | **Amount** | **capital** | **deficit** | **equity** |
| Balance as of December 31, 2024 | 1919420 | $4 | 49585 | $\*)- | $462358 | $(390343) | $72019 |
| Deemed dividend related to issuance of preferred stock |  |  |  |  | 4839 | (4839) |  |
| Conversion of Preferred Stock to Common Stock | 42771 | \*)- | (1800) | \*)- |  |  | \*)- |
| Exercise of Prefunded warrants to common stock | 142984 | \*)- |  |  | 1750 |  | 1750 |
| Stock-based compensation | 30155 | \*)- |  |  | 2342 |  | 2342 |
| Issuance of preferred stock, net of issuance cost |  |  | 6800 | \*)- | 6815 |  | 6815 |
| Net loss |  |  |  |  |  | (9227) | (9227) |
| Balance as of March 31, 2025 | 2135330 | $4 | 54585 | $\*)- | $478104 | $(404409) | $73699 |

---

\*) Represents an amount lower than $1.

(\*\*) See note 1e regarding reverse share split.

The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (UNAUDITED)**

**U.S. dollars in thousands**

---

| | | |
|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  |
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
| Cash flows from operating activities: |  |  |
| Net loss | $(8249) | $(9227) |
| &nbsp;&nbsp;Adjustments required to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 1441 | 2342 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in operating lease right of use assets | 110 | 110 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 463 | 1162 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and impairment  | 61 | 94 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant liability | (177) | (1115) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest on short term bank deposits | (21) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash financial expenses | 159 | 293 |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in trade receivables, net | (75) | 1597 |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in other accounts receivable, prepaid expense and long-term assets  | 269 | (369) |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease in inventories | 144 | 130 |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in trade payables | 535 | (300) |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease in other accounts payable and accrued expenses | (341) | (1666) |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease in deferred revenues | (213) | (278) |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease in operating lease liabilities | (116) | (126) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (15) | 680 |
| Net cash used in operating activities | (6025) | (6673) |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Investment in short term bank deposit | (5000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from maturity of short-term bank deposit | 4200 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment | (31) | (31) |
| &nbsp;&nbsp;&nbsp;&nbsp;Disposals of property and equipment | 5 |  |
| Net cash used in investing activities | (826) | (31) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of preferred stock, net of issuance costs |  | 6815 |
| Net cash provided by financing activities |  | 6815 |
| Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | (6851) | 111 |
| &nbsp;&nbsp;Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents | 25 | (21) |
| &nbsp;&nbsp;Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 21803 | 27764 |
| &nbsp;&nbsp;Cash, cash equivalents and restricted cash and cash equivalents at end of period | $14977 | $27854 |
| Supplemental disclosure of cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for interest on long-term loan | $965 | $937 |
| Non-cash activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercise of pre-funded warrants to common stock | $1266 | $1750 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred cost related to ATM offering | $137 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment on credit | $5 | $— |

---

The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements.

[**Table of Contents**](#TOC)

**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 1: - GENERAL
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. DarioHealth Corp. (the "Company" or "DarioHealth") was incorporated in the State of Delaware and commenced operations on August 11, 2011.

DarioHealth is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching, DarioHealth has developed an approach with the intent to empower individuals to adjust their lifestyle in holistic way.

DarioHealth's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

DarioHealth's digital therapeutic platform has been designed with a 'user-first' strategy, focusing on the user's needs first and foremost, and user experience and satisfaction. User satisfaction is constantly measured and drives all Company processes, including our technology design.

The Company has one reporting unit and one operating segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The Company has a wholly owned subsidiary, LabStyle Innovation Ltd. ("LabStyle"), which was incorporated and commenced operations on September 14, 2011, in Israel. Its principal business activity is to hold the Company's intellectual property and to perform research and development, manufacturing, marketing, and other general and administrative business activities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. On February 15, 2024, the Company acquired Twill, pursuant to the terms of an Agreement and Plan of Merger (the "Twill Agreement"). Pursuant to the provisions of the Twill Agreement, Twill Merger Sub, Inc. ("Merger Sub") was merged with and into Twill, the separate corporate existence of Merger Sub ceased and Twill continued as the surviving company and a wholly owned subsidiary of the Company. Twill is a clinical grade technology company working to shorten the distance between need and care by configuring personalized digital therapeutics and care solutions at scale for the modern healthcare cloud. Twill's Intelligent Healing Platform(tm): integrates artificial intelligence (AI) with empathy, making healing more personal, precise, and connected for the entire care journey. Twill deploys a full spectrum of science-backed care solutions-including digital therapeutics, coaching, community, and well-being products for pharma, health plans, enterprises, and individuals everywhere.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. The Company has, through its wholly owned subsidiary PsyInnovations Inc., a company located in India, DarioHealth Services, which serves as the Company's primary research and development center. DarioHealth Services is engaged in software development and other R&D activities in support of the Company's operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Effective as of August 28, 2025, the Company effected a reverse stock split of its outstanding shares of Common Stock at a ratio of twenty -for- one (the "Reverse Stock Split"). The Reverse Stock Split was approved by the Company's board of directors under authority granted by the Company's stockholders at the Company's 2025 Annual Meeting of Stockholders held on July 23, 2025, and was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on August 25, 2025. All issued and outstanding share and per share amounts included in the accompanying consolidated financial statements have been adjusted to reflect the Reverse Stock Split for all periods presented.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. The Company has incurred recurring losses and negative cash flows since inception and has an accumulated deficit of $460,327 . The Company expects to incur future net losses and its transition to profitability is dependent upon, among other things, the successful development and commercialization of the Company's products and the achievement of a level of revenues adequate to support the cost structure. Until the Company achieves profitability or generates positive cash flows, it will continue to be dependent on raising additional funds to fund its operations. The Company intends to fund its future operations including meeting its covenants related to loan facility through cash on hand, additional private and/or public offerings of debt or equity securities or a combination of the foregoing. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its product offerings.

For the three months ended March 31, 2026, the Company used approximately $6,025 of cash in operations. Based on the Company's updated cash flow projections as of the date of these financial statements, and the conditions noted above, there is substantial doubt about the Company's ability to continue as a going concern for twelve months from the date of issuance of these interim condensed consolidated financial statements. The accompanying condensed interim consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES
***Basis of Presentation***

The accompanying unaudited interim condensed consolidated financial statements as of March 31, 2026 have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the unaudited interim condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair statement of the Company's consolidated financial position as of March 31, 2026 and the Company's consolidated results of operations and cash flows for the three months ended March 31, 2026. Results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

***Use of Estimates***

Preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and judgments that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. These estimates are based on management's knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.

***Significant Accounting Policies***

&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 are applied consistently in these unaudited interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Concentrations of credit risk:

Financial instruments that potentially subject the Company to credit risks primarily consist of cash and cash equivalents, short-term deposits, restricted deposits, and trade receivables. For cash and cash equivalents, the Company is exposed to credit risks in the event of default by the financial institutions to the extent that amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.

For trade receivables, the Company is exposed to credit risk in the event of non-payment by customers to the extent of the amounts recorded on the accompanying consolidated balance sheets.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Balance at<br>beginning of period | <br>Additions | <br>Deduction | Balance at<br>end of period |
| Three months ended March 31, 2026 |  |  |  |  |
| Allowance for credit losses | $158 | $— | $(21) | $137 |
| Three months ended March 31, 2025 |  |  |  |  |
| Allowance for credit losses | $169 | $28 | $(6) | $191 |

---

The Company has no off-balance-sheet concentration of credit risk.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

**NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)**

As of March 31, 2026 and December 31, 2025, the Company's major customer accounted for 39.5% and 30.5%, respectively, of the Company's accounts receivable balance. For the three months ended March 31, 2026 and March 31, 2025, the Company's major customers accounted for 10.2% and 19.1%, respectively, of the Company's revenue in the period.

&nbsp;&nbsp;&nbsp;&nbsp;c. Recently issued Accounting Pronouncements

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) - Disaggregation of Income Statement Expenses. The ASU requires, among other items, additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included in the Statements of Operations. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the effect of adopting this ASU on its disclosures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. The ASU provides a practical expedient for estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025, and interim reporting periods in those years. ASU 2025-05 did not have a material impact on the Company's consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The ASU replaces the existing project-stage model with a principles-based approach to determine when capitalization of costs should begin. ASU 2025-06 is effective for annual reporting periods beginning after December 15, 2027, on a prospective basis, with early adoption permitted. The Company is currently evaluating the potential impact of adopting this ASU.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. The guidance is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. The Company is currently evaluating the effect of adopting this ASU.

#### NOTE 3: - INVENTORIES

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,** <br>**2025** |
| Raw materials | $815 | $751 |
| Finished products | 3357 | 3565 |
|  | $4172 | $4316 |

---

During the three months periods ended March 31, 2026 and March 31, 2025, total inventory write-down expenses amounted to $0 and $174, respectively.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 4: - REVENUES
The Company is operating a multi-condition healthcare business, empowering individuals to manage their chronic conditions and take steps to improve their overall health. The Company generates revenues from contracts with enterprise business market groups to provide digital therapeutics solutions for individuals to receive access to services through the Company's commercial arrangements Business-to-Business-to-Consumer ("B2B2C"); revenues from B2B2C arrangements for the three months ended March 31, 2026 were $2,716. The Company also generates revenue directly from individuals through à la carte offering and membership plans ("Consumers"); Consumers revenues for the three months ended March 31, 2026 were $2,868. For the three months ended March 31, 2025, revenues from B2B2C arrangements were $4,737, and Consumer revenues were $2,015.

*Deferred Revenue*

The Company recognizes contract liabilities, or deferred revenues, when it receives advance payments from customers prior to the satisfaction of the Company's performance obligations. The balance of deferred revenues approximates the aggregate amount of the transaction price allocated to the unsatisfied performance obligations at the end of the reporting period. The Company expects to recognize approximately $501 over the next 12 months and the remainder thereafter.

The Company elected to not disclose information about remaining performance obligations for which the variable consideration is allocated to a wholly unsatisfied promise to transfer a distinct good or service that is subject to the variable consideration allocation exception.

The following table presents the significant changes in the deferred revenue balance during the three months ended March 31, 2026:

---

| | |
|:---|:---|
| Balance, beginning of the period | $719 |
| New performance obligations | 618 |
| Reclassification to revenue as a result of satisfying performance obligations | (831) |
| Balance, end of the period | $506 |

---

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

**NOTE 4: - REVENUES (Cont.)** 

*Costs to Fulfill a Contract*

The Company defers costs incurred to fulfill contracts that: (1) relate directly to the contract; (2) are expected to generate resources that will be used to satisfy the Company's performance obligations under the contract; and (3) are expected to be recovered through revenue generated under the contract. Contract fulfillment costs are expensed as the Company satisfies its performance obligations and recorded into cost of revenue.

Costs to fulfill a contract are recorded in other accounts receivable and prepaid expenses and long-term assets.

Costs to fulfill a contract consist of (1) deferred consumer hardware costs incurred in connection with the delivery of services that are deferred, and (2) deferred costs incurred related to future performance obligations which are capitalized.

Costs to fulfill a contract as of March 31, 2026 and December 31, 2025 consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,** <br>**2025** |
| Costs to fulfill a contract, current | $266 | $258 |
| Costs to fulfill a contract, noncurrent | 251 | 176 |
| Total costs to fulfill a contract | $517 | $434 |

---

Costs to fulfill a contract were as follows:

---

| | |
|:---|:---|
|  | **Costs to** <br>**fulfill a contract** |
| Beginning balance as of December 31, 2025 | $434 |
| Additions | 181 |
| Cost of revenue recognized | (98) |
| Ending balance as of March 31, 2026 | 517 |

---

[**Table of Contents**](#TOC)

**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

**NOTE 5: - DEBT**

*Callodine Loan Facility*

On April 30, 2025, the Company refinanced its previous $30,000 credit facility with a new $32,500 credit agreement (the "Credit Agreement"), by and among the Company as borrower, the financial institutions party thereto from time to time as lenders, and Callodine Commercial Finance, LLC (in its capacity as agent for all lenders, "Agent," and collectively with other lenders, "Lenders") (the "Callodine Loan Facility"). Under the terms of the Credit Agreement, each Lender agreed to make a multi-draw term loan (each a "Term Loan") in which the Company borrowed $32,500 at the time of closing on April 30, 2025. In addition, the Company may at its option draw an aggregate of up to an additional $17,500. $2,500 of such additional Term Loan is subject to the achievement of certain revenue and gross margin thresholds. $15,000 of such additional Term Loan is subject to the discretion of the Agent and the Lenders. The Credit Agreement has a five-year term that matures in April 2030. Principal repayments on the Term Loan are not due until May 2028, at which point the Company is required to make equal quarterly principal installments in the amount of $1,367, with all remaining outstanding principal due on the Term Loan Maturity Date of April 30, 2030.

The outstanding principal balance under the loan shall bear interest at a per annum rate of interest equal to (i) the Secured Overnight Financing Rate ("SOFR"), (as defined in the Credit Agreement) plus (ii) seven and three-quarters of one percent (7.75%). Upon maturity and/or upon an event of default (or upon any acceleration), interest shall automatically accrue without notice to the Company at a rate per annum equal to the lesser of (i) three percent (3%) over the Contract Rate (as defined in the Credit Agreement), or (ii) the maximum rate of interest permitted to be charged by applicable laws or regulations until paid. The Company paid certain fees with respect to the Term Loan, including a closing fee and an agent fee. Voluntary prepayments of the Term Loan prior to the third anniversary of the closing are also subject to certain pre-payment penalties.

In connection with the funding of the closing amount, the Company agreed to issue the Lenders a warrant to purchase an aggregate of 105,707 shares of our Common Stock, with an exercise price of $16.56, which shall have a term of seven years from the issuance date. In addition, up to $2,500 of the loaned amount can be converted into shares of our Common Stock at a price of $19.87 per share.

The Company concluded that the Callodine Loan Facility and the Warrant are freestanding financial instruments since these instruments are legally detachable and separately exercisable. The Company has concluded that the Warrant meets all the conditions to be classified as equity pursuant to ASC 480 and ASC 815-40. The Callodine Loan Facility is measured at amortized cost.

With respect to the Initial Commitment Amount only, the fair value of the Callodine Loan Facility is recognized in connection with the Company's Credit Agreement. The fair value of the Callodine Loan Facility was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the Callodine Loan Facility, which is reported within non-current liabilities (Maturity Date - April 30, 2030) on the consolidated balance sheets, was estimated by the Company as of April 30, 2025 such that the value of the instruments granted by the Company under the Callodine Loan Facility equals the net principal amount (net of origination fees).

The Callodine Loan Facility incorporates comparisons to instruments with similar covenants, collateral, and risk profiles and was obtained using a discounted cash flow technique. On the date of Callodine Loan Facility origination, or April 30, 2025, the discount rate was arrived at by calibrating the loan amount of $32,500 with the fair value of the warrants of $1,234 and the loan terms interest rate equal to the greater of (i) The SOFR, and(ii) 4.0% plus a margin of 7.75%. The implied internal rate of return of the loan resulted with B rating U.S. dollar zero coupon discount curve plus a 11.473% credit curve. Interest expense related to the Callodine Loan Facility that measured at amortized cost were recorded within "Interest expense" in the consolidated statements of comprehensive loss.

On November 5, 2025, the Company entered into an Amendment to the Credit Agreement with the Lenders. Among other things, the amendment (i) resets financial covenants and waives financial-covenant testing for the second and third quarters of 2025; (ii) replaces the minimum cash covenant with a $10,000 minimum consolidated unencumbered liquid assets covenant; (iii) adds monthly 13-week cash-flow reporting when liquidity is below certain amount (subject to an EBITDA exception); (iv) clarifies that Tranche B is uncommitted and at lender discretion; and (v) increases the exit fee by $150 (waived if a change-of-control prepayment fee is triggered). In connection therewith, the Company repriced the Warrant to purchase up to 105,707 shares of Common Stock issued to the lenders on April 30, 2025, at an exercise price $16.56 per share, to permit an amendment to the exercise price of such Warrants to $15.35. In addition, conversion right of the lender in the amount of $2,500 was amended to a conversion price of $15.35 per share. As of March 31, 2026, the Company was in compliance with all applicable covenants under the Credit Agreement, as amended.

[**Table of Contents**](#TOC)

**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

**NOTE 5: - DEBT (Cont.)**

*Orbimed Warrant*

On June 9, 2022 the Company entered into a Credit Agreement, with OrbiMed Royalty and Credit Opportunities III, LP ("Orbimed"), as the lender for a five-year senior secured credit facility in an aggregate principal amount of up to $50 million, of which $25 million was made available on the closing date and up to $25 million was to be made available on or prior to June 30, 2023, subject to certain revenue requirements (the "Orbimed Loan").

On June 9, 2022 (the closing date of the Orbimed Loan, which was repaid in May 2023), the Company agreed to issue Orbimed a warrant (the "Orbimed Warrant") to purchase up to 11,330 shares of the Company's Common Stock, at an exercise price of $132.40 per share, which shall have a term of 7 years from the issuance date. The Orbimed Warrant contains customary share adjustment provisions, as well as weighted average price protection in certain circumstances but in no event will the exercise price of the Warrant be adjusted to a price less than $80.00 per share. Following the issuance and sale of the Company's Series C Preferred Stock in February 2024, and as a result of a certain price protection provision in the Orbimed Warrant, the exercise price of the Orbimed Warrant was adjusted to a price per share of $80.

The Company has concluded that the Orbimed Warrant is not indexed to the Company's own stock and should be recorded as a liability measured at fair value with changes in fair value recognized in earnings. The Company remeasurement income related to the Orbimed Warrant for the three months ended March 31, 2026, were $20, compared to $30 for the three months ended March 31, 2025.

*Pre-Funded Warrants*

On February 15, 2024, as part of the acquisition of Twill the Company issued Pre-Funded Warrants to purchase up to 500,020 shares of Company Common Stock, issuable to a trust (the "Trust") formed for the benefit of certain equity and debt holders of Twill.

The Company has classified the Pre-Funded Warrants as liability pursuant to ASC 815-40 since the Pre-Funded Warrants do not meet all the equity classification conditions. Accordingly, the Company measured the Pre-Funded Warrants at their fair value. The Pre-Funded Warrants liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of comprehensive loss.

In February 2025, a total of 125,005 Pre-Funded Warrants were cashless exercised into 124,985 shares of Common Stock.

In February 2026, a total of 125,005 Pre-Funded Warrants were cashless exercised into 124,982 shares of Common Stock. This represented the final tranche of the Pre-Funded Warrants issued in connection with the Twill acquisition, and as of March 31, 2026, no Pre-Funded Warrants related to the acquisition of Twill remain outstanding.

During the three months ended March 31, 2026 and March 31, 2025, the Company recognized $157 and $1,085, respectively, of remeasurement income related to the Pre-Funded Warrants. The estimated fair value of the Pre-Funded Warrants liabilities was determined using observable market inputs, primarily the quoted market price of the Company's common stock, and is classified within Level 2.

**NOTE 6: - FAIR VALUE MEASUREMENTS**

Under U.S. GAAP, fair value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction between market participants and requires that assets and liabilities carried at fair value are classified and disclosed in the following three categories:

---

| | |
|:---|:---|
| Level 1 - | Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. |

---

Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment, and the investments are categorized as Level 3.

[**Table of Contents**](#TOC)

**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

**NOTE 6: - FAIR VALUE MEASUREMENTS (Cont.)**

The carrying amounts of cash and cash equivalents, short-term restricted bank deposits, trade receivables, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. In addition, the Callodine Loan Facility approximates its fair value. The Orbimed Warrant liability was measured at fair value using Level 3 unobservable inputs.

The following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
|  | **Fair Value** | **Level 1** | **Level 2** | **Level 3** |
| Financial assets: |  |  |  |  |
| Cash and cash equivalents: |  |  |  |  |
| U.S. treasury notes | $6367 | $— | $6367 | $— |
| Total financial assets | $6367 | $— | $6367 | $— |
| Financial liabilities: |  |  |  |  |
| Orbimed Warrant liability | $23 | $— | $— | $23 |
| Total financial liabilities | $23 | $— | $— | $23 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
|  | **Fair Value** | **Level 1** | **Level 2** | **Level 3** |
| Financial assets: |  |  |  |  |
| Cash and cash equivalents: |  |  |  |  |
| U.S. treasury notes | $12761 | $— | $12761 | $— |
| Total financial assets | $12761 | $— | $12761 | $— |
| Financial liabilities: |  |  |  |  |
| Orbimed Warrant liability | 43 |  |  | 43 |
| Pre-Funded Warrant liability | 1423 |  | 1423 |  |
| Total financial liabilities | $1466 | $— | $1423 | $43 |

---

[**Table of Contents**](#TOC)

**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 7: - COMMITMENTS AND CONTINGENT LIABILITIES
From time to time, the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.

*Royalties*

The Company has a liability to pay future royalties to the Israeli Innovation Authority (the "IIA") for participation in programs sponsored by the Israeli government for the support of research and development activities. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues (based on the U.S. dollar) generated from such projects, up to 100% of the grants received. Royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the products and in the absence of such sales, no payment is required.

In connection with specific research and development activities, Physimax Technology ("Physimax"), prior to its acquisition by the Company, received $1,012 of participation payments from the IIA. The Company's total commitment for royalties payable with respect to future sales, based on IIA participation received, net of royalties accrued or paid, totaled $976 as of December 31, 2025, and $981 as of March 31, 2026.

During the three months ended March 31, 2026 and March 31, 2025, the Company did not record significant IIA royalties related to the acquisition of Physimax Technology.

**NOTE 8: - INTANGIBLE ASSETS**

---

| | | | |
|:---|:---|:---|:---|
| a. Finite-lived intangible assets: |  |  |  |
|  | **March 31,**  | **December 31,**  | **Weighted Average** |
|  | **2026** | **2025** | **Remaining Life** |
|  |  |  | **As of March 31, 2026** |
| Original amounts: |  |  |  |
| Technology | $22580 | $22580 | 5.8 |
| Brand | 376 | 376 |  |
| Customer Relationship Healthcare | 13791 | 13791 | 9.8 |
| Domains | 23 | 23 |  |
|  | 36770 | 36770 |  |
| Accumulated amortization: |  |  |  |
| Technology | 18456 | 18279 |  |
| Brand | 376 | 376 |  |
| Customer Relationship Healthcare | 2464 | 2178 |  |
| Domains | 6 | 6 |  |
|  | 21302 | 20839 |  |
| Intangible assets, net | $15468 | $15931 |  |
| b. Estimated amortization expense: |  |  |  |
| For the year ended December 31, |  |  |  |
| Remainder of 2026 | 1414 |  |  |
| 2027 | 1877 |  |  |
| 2028 | 1882 |  |  |
| 2029 | 1877 |  |  |
| Thereafter | 8418 |  |  |
|  | $15468 |  |  |

---

c. Amortization expenses for the three months ended March 31, 2026 and March 31, 2025 were $463 and $1,162, respectively.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 9: - RELATED PARTIES TRANSACTIONS
In February 2025, the Company appointed a new non-executive director to its Board. The director is a member of a consulting firm that has provided investment and business consulting services to the Company since 2021 under a consulting agreement. Pursuant to the consulting agreement, the Company agreed to pay the consultant a monthly cash retainer upon the successful completion of certain milestones. In addition, the Company agreed to issue 7,500 restricted shares of Common Stock to the consulting firm, vesting quarterly over a four-year period. As of December 31, 2025, the consulting firm received approximately 12,900 shares of Common Stock and warrants to purchase up to 5,000 shares of Common Stock. In addition, in February 2025, the Company entered into a second amendment to the consulting agreement, pursuant to which it agreed to pay the consulting firm a fixed monthly cash retainer of $10. During the three months ended March 31, 2026, and March 31, 2025 the Company recorded share-based compensation expenses related to this service provider in the amounts of $65 and $65 respectively.

#### NOTE 10: - STOCKHOLDERS' EQUITY
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a.* *Common Stock* 

The holders of Common Stock have the right to one vote for each share of Common Stock held of record by such holder with respect to all matters on which holders of Common Stock are entitled to vote, to receive dividends as they may be declared at the discretion of the Company's Board of Directors and to participate in the balance of the Company's assets remaining after liquidation, dissolution or winding up, ratably in proportion to the number of shares of Common Stock held by them after giving effect to any rights of holders of preferred stock. Except for contractual rights of certain investors, the holders of Common Stock have no pre-emptive or similar rights and are not subject to redemption rights and carry no subscription or conversion rights.

On July 23, 2025, the Company's stockholders voted to approve an amendment to the Certificate of Incorporation of the Company to increase the number of authorized Common Stock from one hundred sixty million (160,000,000) shares, $0.0001 par value per share, to four hundred million (400,000,000) shares, $0.0001 par value per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*b.* *ATM Offering* 

On March 30, 2026, the Company entered into an At-The-Market Sales Agreement (the "ATM"), allowing the Company to sell its common stock for aggregate sales proceeds of up to $20,000 from time to time and at various prices, subject to the conditions and limitations set forth in the sales agreement. If shares of the Company's common stock are sold, there is a three percent fee paid to the sales agent. As of March 31, 2026, the Company had not sold any shares under the ATM and there were $20,000 remaining funds available under the ATM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*c.* *Pre-Funded Warrant Exercises* 

On February 5, 2026, out of the pre-funded warrants that were issued in September 2025, 62,016 were exercised on a cashless basis into 62,016 shares of Common Stock. As of March 31, 2026, the Company's total outstanding prefunded warrants were exercisable into 2,377,553 shares of Common Stock.

On March 17, 2025, from the pre-funded warrants that were issued in July 2020, 18,015 were exercised on a cashless basis into 17,999 shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*d.* *Preferred Stock* 

On January 7, 2025, the Company entered into securities purchase agreements (each, a "Series D Purchase Agreement") with accredited investors relating to an offering (the "Series D Offering") and the sale of an aggregate of (i) 4,950 shares of newly designated Series D-2 Preferred Stock (the "Series D-2 Preferred Stock"), and (ii) 1,850 shares of Series D-3 Preferred Stock (the "Series D-3 Preferred Stock"), at a purchase price of $1,000 for each share of preferred stock. As a result of the sale of the preferred stock, the aggregate gross proceeds to the Company from the Series D Offering are approximately $6,800. The closing of the Series D-2 Preferred Stock, and Series D-3 Preferred Stock occurred on January 14, 2025.

The conversion of the preferred stock was subject to stockholder approval. In addition, according to the original certificates of designation, the preferred stock will automatically convert into shares of Common Stock, subject to certain beneficial ownership limitations, on the 12-month anniversary of the issuance date. The holders of preferred stock will also be entitled to dividends equal to a number of shares of Common Stock equal to ten percent (10%) of the number of shares of Common Stock issuable upon conversion of the preferred stock then held by such holder for each full quarter anniversary of holding for a total of four quarters from the Closing Date, all issuable upon conversion of the preferred stock.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 10: - STOCKHOLDERS' EQUITY (Cont.)
In September 2025, all outstanding shares of Series D, D-1, D-2 and D-3 Preferred Stock, totaling 25,605 shares, were converted into 1,600,043 and 776,719 shares of Common Stock and pre-funded warrants, respectively, and as of September 30, 2025, no shares of Series D, D-1, D-2 and D-3 Preferred Stock remains outstanding.

During the three months period ended March 31, 2025, the Company accounted for the dividend shares of Common Stock upon the dividend shares earned by Series D and D-1 Preferred Stock as a deemed dividend for an amount of $2,226. No deemed dividend was recorded during the three months period ended March 31, 2026 as all D and D-1 Preferred Stock were converted in September 2025.

During the three months period ended March 31, 2025, the Company accounted for the dividend shares of Common Stock upon the dividend shares earned by Series D-2 and D-3 Preferred Stock as a deemed dividend for an amount of $419. No deemed dividend was recorded during the three months period ended March 31, 2026 as all D-2 and D-3 Preferred Stock were converted in September 2025.

In February 2025, a total of 125 shares of certain Series C Convertible Preferred Stock were converted into 3,791 shares of Common Stock.

During the three months period ended March 31, 2025, the Company accounted for the dividend shares of Common Stock upon the dividend shares earned by Series C, C-1 and C-2 Preferred Stock as a deemed dividend for an amount of $2,194. No deemed dividend was recorded during the three months period ended March 31, 2026 as all C, C-1 and C-2 Preferred Stock were converted in September 2025.

In March 2025, a total of 1,675 shares of certain Series A-1 Convertible Preferred Stock were converted into 38,980 shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*e.* *Lock-Up Agreements* 

In February, 2026, pursuant to the A&R Lock-Up Agreements entered into in December 2024, as subsequently amended in May and October 2025, the Company issued an aggregate of 204,851 shares of Common Stock and 104,090 pre-funded warrants upon conversion of the lock-up consideration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*f.* *Stock plans* 

On October 14, 2020, the Company's stockholders approved the 2020 Plan. Under the 2020 Plan, options to purchase shares of Common Stock may be granted to employees and non-employees of the Company or any affiliate, each option granted can be exercised to one share of Common Stock.

In January 2025, pursuant to the terms of the 2020 Plan as approved by the Company's stockholders, the Company increased the number of shares authorized for issuance under the 2020 Plan by 327,052 shares, from 567,832 to 894,883.

On July 23, 2025, the Company's stockholders resolved to amend and restate the Company's 2020 Plan, to (i) provide that for each of the calendar years ending on December 31, 2026, December 31, 2027, December 31, 2028, December 31, 2029 and December 31, 2030, the number of shares available under the 2020 Plan shall be increased by an additional number of shares of the Company's Common Stock, equal to six percent (6%) of the number of shares of Common Stock issued and outstanding on a fully diluted basis on the immediately preceding December 31; and (ii) authorize the grant of restricted stock units as a permissible form of award under the 2020 Plan.

In January 2026, pursuant to the terms of the 2020 Plan as approved by the Company's stockholders, the Company increased the number of shares authorized for issuance under the 2020 Plan by 636,131 shares, from 894,883 to 1,531,014.

On January 29, 2026 the Company's stockholders resolved to amend the Company's 2020 Plan, to increase the number of shares authorized for issuance under the 2020 Equity Incentive Plan by 500,000 shares, from 1,531,014 to 2,031,014.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*g.* *Stock Option, Restricted Stock and Warrant Grants* 

2026 Grants

Employees and Consultants: During 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") approved grants of an aggregate of 2,127 restricted shares of Common Stock to employees and Consultants of the Company, and approved grants of options to purchase an aggregate of 8,500 shares of Common Stock to employees of the Company, at exercise prices ranging from $10.14 to $11.38 per share. The time-vesting restricted shares and stock options vest over three years commencing on the respective

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 10: - STOCKHOLDERS' EQUITY (Cont.)
grant dates, and the options have a ten-year contractual term. All such restricted shares and options were issued pursuant to the Company's Amended and Restated 2020 Equity Incentive Plan, as amended (the "2020 Plan"). In addition, during 2026, the Compensation Committee approved an amendment to certain previously issued restricted stock awards to accelerate the vesting of 6,250 previously unvested restricted shares.

Service Providers: During 2026, the Compensation Committee approved a monthly grant of shares of the Company's Common Stock equal to $15 of restricted shares to certain service providers per month, to be granted quarterly during the period that the certain consulting agreement remains in effect. During the three months ended March 31, 2026 no restricted unregistered shares of Common Stock, were issued to certain service provider under this approval the Company recorded compensation expense in the amount of $30.

2025 Grants

Employees and Consultants: During 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") approved a grant of 28,750 restricted shares of Common Stock to certain service providers and approved the grant of warrants to purchase up to 52,500 shares of Common Stock, at an exercise price of $12.80 per share, to certain consultants. The warrants are exercisable into shares of Common Stock on or before February 10, 2028. All such restricted shares and warrants were issued pursuant to the Company's Amended and Restated 2020 Equity Incentive Plan, as amended (the "2020 Plan").

Directors: During 2025, the Compensation Committee approved a grant of 1,500 restricted shares of Common Stock to a director of the Company and approved an amendment to certain previously issued awards of restricted Common Stock in the aggregate amount of 1,750 shares, granted to the director, to permit an immediate acceleration of the unvested portion of the prior awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*h.* Transactions related to the grant of options to employees, directors, and non-employees under the above plans and non-plan options during the three-months period ended March 31, 2026, were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | | **Weighted**<br>**average**<br>**remaining**<br>**contractual**<br>**life** | <br>**Aggregate**<br>**Intrinsic**<br>**value** |
|  | <br>**Number of**<br>**options\*\*** | $**Years** | **$** |
| Options outstanding at beginning of period | 336768  | 8.16 | 4  |
| Options granted | 8500 |  |  |
| Options exercised |  |  |  |
| Options expired | (46885) |  |  |
| Options forfeited | (7067) |  |  |
| &nbsp;&nbsp;Options outstanding at end of period | 291316  | 8.25 | 2  |
| &nbsp;&nbsp;Options vested and expected to vest at end of period | 103970  | 8.16 |  |
| &nbsp;&nbsp;Exercisable at end of period | 137020  | 7.75 | 2  |

---

(\*\*) See note 1e regarding reverse share split.

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on the last day of the first quarter of 2026 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on March 31, 2026. This amount is impacted by the changes in the fair market value of the Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*i.* Transactions related to the grant of restricted shares to employees and directors under the above plans during the three-months period ended March 31, 2026, were as follows:

---

| | |
|:---|:---|
|  | **Number of**<br>**Restricted shares\*\*** |
| Restricted shares outstanding at beginning of year | 613465 |
| Restricted shares granted | 2127 |
| Restricted shares forfeited | (3031) |
| &nbsp;&nbsp;Restricted shares outstanding at end of period | 612561 |

---

(\*\*) See note 1e regarding reverse share split.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

#### NOTE 10: - STOCKHOLDERS' EQUITY (Cont.)
As of March 31, 2026, the total unrecognized estimated compensation cost related to non-vested stock options and restricted shares granted prior to that date was $4,267 which is expected to be recognized over a weighted average period of approximately one (1.03) year.

The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing model.

Number of restricted shares vested during the three months period ended March 31, 2026 amounts to 19,876.

The fair value of the restricted shares granted during the three months period ended March 31, 2026 amounts to $22.

The following table presents the assumptions used to estimate the fair values of the options granted to employees, directors, and non-employees in the period presented:

---

| | | |
|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  |
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
| Volatility | 98.97-101.10% | —% |
| Risk-free interest rate | 3.79-3.83% | —% |
| Dividend yield | —% | —% |
| Expected life (years) | 5.88 |  |

---

The total compensation cost related to all of the Company's stock-based awards recognized during the three-month periods ended March 31, 2026 and 2025 was comprised as follows:

---

| | | |
|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  |
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
| Cost of revenues | $5 | $10 |
| Research and development | 92 | 526 |
| Sales and marketing | 133 | 815 |
| General and administrative | 1211 | 991 |
| Total stock-based compensation expenses | $1441 | $2342 |

---

#### NOTE 11: - SELECTED STATEMENTS OF OPERATIONS DATA
Other Financial income, net:

---

| | | |
|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  |
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
| Bank charges | $23 | $34 |
| Foreign currency adjustments expenses, net | 48 | (42) |
| Interest income | (160) | (289) |
| Remeasurement of Avenue loan |  | 1207 |
| Remeasurement of warrant liability | (177) | (1114) |
| Other financial income, net | $(266) | $(204) |

---

**NOTE 12:- SEGMENT REPORTING**

The Company identifies operating segments in accordance with ASC Topic 280, "Segment Reporting," as components of an entity for which discrete financial information is available and is regularly reviewed by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and evaluating financial performance.

The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is regularly evaluated by the Chief Operating Decision Maker ("CODM"), which is the Company's chief executive officer, in deciding how to allocate resources and assess performance. The Company's CODM evaluates the Company's financial information and resources and assesses the performance of these resources on a consolidated basis. There is no expense or asset information that are supplemental to those disclosed in these consolidated financial statements, that are regularly provided to the CODM. The allocation of resources and assessment of performance of the operating segment is based on consolidated net loss as shown in our consolidated statement of comprehensive loss. The CODM considers net loss in the annual forecasting process and reviews actual results when making decisions about allocating resources.

[**Table of Contents**](#TOC)

#### DARIOHEALTH CORP. AND ITS SUBSIDIARIES
**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

**NOTE 12:- SEGMENT REPORTING (Cont.)**

Since the Company operates as one operating segment, financial segment information, including profit or loss and asset information, can be found in the consolidated financial statements.

*Geographic Information*

● As of March 31, 2026, the majority of the Company's long-lived assets are located in Israel and India.

● As of March 31, 2026, the majority of the Company's revenue is generated in the U.S.

**NOTE 13: - INCOME TAXES**

During the three months ended March 31, 2026, the Company recorded tax expenses in the amount of $57, compared to $22 for the three months ended March 31, 2025.

The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

**NOTE 14: - BASIC AND DILUTED NET EARNINGS (LOSS) PER COMMON STOCK**

The Company computes net loss per share of Common Stock using the two-class method. Basic and diluted net earnings or loss per share is computed using the weighted-average number of shares outstanding during the period. This calculation includes the total weighted average number of the Common Stock, which includes prefunded warrants.

The total number of potential shares of Common Stock related to outstanding options, warrants and preferred shares excluded from the calculations of diluted net loss per share due to their anti-dilutive effect were 919,809 and 3,453,722 for the three months ended March 31, 2026 and March 31, 2025, respectively.

The following table sets forth the computation of the Company's basic net earnings (loss) per Common Stock:

---

| | | |
|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  |
|  | **March 31,** | **March 31,** |
|  | **2026** | **2025** |
| Net loss | $8248858 | $9227162 |
| Deemed dividend  |  | 4838622 |
| Less: loss attributable to participating preferred stock |  | 7271112 |
| Net loss attributable to common stock shareholders used in computing basic net loss per share | $8248858 | $6794672 |
| Weighted average number of common stock used in computing basic loss per share | 6582297 | 2368516 |
| Basic and diluted net loss per common stock  | $1.25 | $2.87 |

---

[**Table of Contents**](#TOC)

**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)**

**U.S. dollars in thousands (except stock and per share data)**

**NOTE 15: - SUBSEQUENT EVENTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Subsequent to March 31, 2026 and through the date of this Quarterly Report on Form 10-Q, we sold an aggregate of 7,252 shares under the ATM Program for gross proceeds of approximately $54 and net proceeds of approximately $53, after deducting commissions and offering expenses. As of May 13, 2026, there were $19,946 remaining funds available under the ATM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.On April 5, 2026, the Company, through its wholly-owned subsidiary LabStyle, entered into a sublease agreement (the "Sublease") pursuant to which LabStyle agreed to sublease a portion of its leased office premises located in Caesarea, Israel to an unrelated third party. Under the Sublease, LabStyle is expected to receive a monthly consideration of approximately $21 over a period of 28 months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. In April 16, 2026 (the "Service Commencement Date"), Dario Health Services, the Company's wholly-owned subsidiary incorporated in India, entered into a lease agreement (the "New Agreement") with Indiqube Spaces Limited for the use of 176 dedicated work units on the fourth floor of Indiqube Vatika Building, Tower-A, Golf Course Road, Sector 54, Gurugram, Haryana, India. The New Agreement has a commitment term of 42 months from the Service Commencement Date. The monthly rent, including management services, under the new lease will be approximately $19 .

[**Table of Contents**](#TOC)

#### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (amounts in thousands except for share and share amounts)
*Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2025. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See "Cautionary Note Regarding Forward-Looking Statements." You should review the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.*

*The following financial data in this narrative are expressed in thousands, except for stock and stock data or as otherwise noted.*

*All information included herein relating to shares or price per share reflects the 20-for-1 reverse stock split effected by us on August 28, 2025.*

We are a vertically integrated health intelligence platform with a mission to power the behavior changes that drive better health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, AI built on that proprietary data, and a behavior change and coaching layer validated through over 100 peer-reviewed clinical studies. We are committed to transforming healthcare by delivering a comprehensive and highly engaging whole-person health platform, which enables us to create a future where healthy change is effortless and accessible to all.

At the core of our mission and vision is engagement. We believe that most existing digital health solutions in the market fail to deliver improved health outcomes because users are not engaged due to a lack of relevance, personalization, consumerization, and longitudinal data and information. We, and our acquired companies, first commercialized our digital behavioral health products in the direct-to-consumer ("D2C") marketplace, and we continue to use the D2C marketplace as a sandbox and laboratory for innovation. These consumers pay for these digital health products out of their own pockets and are therefore the most value-driven among all healthcare consumers. These consumers demanded that we deliver highly engaging user experiences that deliver strong clinical health outcomes for which consumers will pay. The bottom line is that if users are not engaged in digital solutions over a long period of time, they cannot change their behavior and they cannot get healthier - we first deliver engagement followed by sustained behavior change that then leads to measurable health outcomes and improvement. We believe that our D2C marketplace roots and continued focus delivers better user experiences, longer sustained engagement, stronger clinical outcomes, at the most affordable prices, that then delivers the highest return on investment ("ROI") in the industry.

Our whole-person health model includes the following five elements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Physical Health: Focuses on the prevention, and treatment of physical ailments; primarily cardiometabolic and musculoskeletal conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Mental Health: Addresses emotional and psychological well-being, including stress management, as well as clinical anxiety, and depression across all levels of severity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Social and Environmental Factors: Considers influences like socioeconomic status, community resources, housing, and education.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Individualized Care: Tailored user journey and care plans that respect personal goals, cultural values, and life circumstances.

[**Table of Contents**](#TOC)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Integration of Clinical Services: Combines different healthcare providers and systems to deliver seamless care for both physical and mental health needs.

We have created our whole-person healthcare solution through both organic development and acquisitions of leading companies across several therapeutic areas. As a digital health consolidation leader, we have acquired companies that have spent over a decade and nearly $525 million, in combination with our own investment, to develop and deliver the most engaging whole-person health platform in the market to empower individuals to achieve their optimal health through data-driven, precision AI personalized care solutions that integrate the management of physical and mental health needs.

Leveraging advanced analytics, data-driven AI precision and personalization, a deep understanding of consumer behavior, user-centric technology, and a holistic approach, we provide tailored interventions that meet the unique needs of each user to deliver the health industry's highest levels of user activation and sustained engagement. Our digital self-care solutions ensure optimal levels of clinical outcomes with the highest levels of clinical efficacy by empowering users to overcome the psychological, social, and physical barriers to effective and sustainable behavior change.

With our whole-person digital health platform, we address a broad range of health needs, including chronic condition management (e.g., diabetes, hypertension, obesity, and musculoskeletal issues), behavioral health (e.g., stress, anxiety, and depression), and preventive care. By integrating digital therapeutics and well-being solutions with real-time data monitoring and access to professional care teams, we ensure an AI-driven adaptive and continuous care experience that combines digital self-care with virtual coaching and virtual clinical care. As of 2025, our eligible user base spans millions of individuals worldwide, supported by partnerships with employers, health plans, pharmaceutical companies, and providers.

We serve four primary market segments that drive our business model. Our historic roots, as well as those of our largest acquisition, Twill, Inc. ("Twill"), began in the D2C market. We continue to operate in the D2C market in the U.S. and select international markets and use it as an innovation laboratory. From our D2C origins, Dario and Twill expanded into B2B market segments such that these market segments now represent three-fourths of our current revenues. These B2B market segments include medium-to-large employers, national and regional health plans, and global pharmaceutical companies.

Our medium-to-large employer market segment is focused on employers with over 1,000 employees. We go to market through a direct sales force, consultants, brokers, and channel partners.

Our health plan customers include five of the nation's largest organizations where we provide our solutions to their members both nationally and regionally. We have specialized in providing our behavioral health offering to Medicare and Medicaid members.

In total, we had 165 customers in 2026.

We have provided our engagement platform services to a dozen global pharmaceutical companies across nearly as many medical conditions, delivering three value propositions: (1) Top of the Funnel education and awareness to help companies find new patients for their treatments, (2) Mental and physical health support to improve medication adherence, persistence, and compliance, and (3) Patient journey data analytics.

#### Results of Operations
***Comparison of the Three Months Ended March 31, 2026 and March 31, 2025 (dollar amounts in thousands)***

*Revenues*

Revenues for the three months ended March 31, 2026 amounted to $5,584, compared to revenues of $6,752 during the three months ended March 31, 2025, representing a decrease of 17.3%. The decrease in revenues was primarily attributable to a non-recurring revenue from a pharmaceutical partner recognized in the prior-year period. These declines were partially offset by growth in revenues from channel partners and an increase in direct-to-consumer sales.

[**Table of Contents**](#TOC)

*Cost of Revenues*

During the three months ended March 31, 2026, we recorded costs related to revenues in the amount of $2,384, compared to $2,870 during the three months ended March 31, 2025, representing a decrease of 16.9%. The decrease was primarily driven by lower amortization of technology and lower hosting and server expenses, which were partially offset by higher hardware and consumables expenses recorded in the cost of revenues.

Cost of revenues consists mainly of the cost of hardware and consumables production, employees' salaries and related overhead costs, stock-based compensation, depreciation of production lines and related cost of equipment used in production, amortization of technologies, hosting costs, shipping and handling costs, and inventory write-downs.

*Gross Profit*

Gross profit for the three months ended March 31, 2026 amounted to $3,200 (57.3% of revenues), compared to $3,882 (57.5% of revenues) during the three months ended March 31, 2025. The decrease in gross profit as a percentage of revenue for the three months ended March 31, 2026, compared to the three months ended March 31, 2025, resulted mainly from the decrease in revenue and higher hardware and consumables expenses which were partially offset by lower amortization of technology and lower hosting and server expenses. Gross profit for the three months ended March 31, 2026, excluding amortization of acquired technology, stock-based compensation and depreciation, was $3,385 (60.6% of revenues) compared to $4,782 (70.8% of revenues) during the three months ended March 31, 2025.

*Research and Development Expenses*

Our research and development expenses decreased by $1,723, or 41.9%, to $2,385 for the three months ended March 31, 2026, compared to $4,108 for the three months ended March 31, 2025. The decrease in research and development expenses was mainly due to efficiencies and post-merger activities, resulting in a decrease in payroll expenses, subcontractors and consulting and stock-based compensation expenses partially offset by the impact of foreign currency fluctuations resulting from the strengthening of the New Israeli Shekel ("NIS") against the U.S. dollar, as certain expenses are denominated in NIS. Our research and development expenses, excluding stock-based compensation and depreciation, for the three months ended March 31, 2026 were $2,261 compared to $3,542 for the three months ended March 31, 2025.

Research and development expenses consist mainly of employees' salaries and related overhead costs involved in research and development activities, expenses related to (i) our solutions (ii) labor, stock-based compensation, contractors and engineering expenses, (iii) depreciation and maintenance fees related to equipment and software tools used in research and development, and (iv) facilities expenses associated with and allocated to research and development activities.

*Sales and Marketing Expenses*

Our sales and marketing expenses decreased by $975, or 16.6%, to $4,898 for the three months ended March 31, 2026, compared to $5,873 for the three months ended March 31, 2025. The decrease was mainly a result of lower payroll expenses, lower stock-based compensation, partially offset by an increase in digital marketing expenses. Our sales and marketing expenses, excluding stock-based compensation, depreciation and amortization, for the three months ended March 31, 2026 were $4,466 compared to $4,747 for the three months ended March 31, 2025, a decrease of $281.

Sales and marketing expenses consist mainly of employees' salaries and related overhead costs, stock-based compensation, depreciation of customer relationship intangible asset, digital marketing campaigns, trade show expenses, and marketing consultants and subcontractors.

*General and Administrative Expenses*

Our general and administrative expenses decreased by $84, or 2.5%, to $3,226 for the three months ended March 31, 2026, compared to $3,310 for the three months ended March 31, 2025. The decrease was mainly due to lower expenses

[**Table of Contents**](#TOC)

relates to corporate activities such as investor relations, and insurance expenses, and lower accounting and legal fees which were partially offset by an increase in stock-based compensation expenses and the impact of foreign currency fluctuations resulting from the strengthening of the ("NIS") against the U.S. dollar, as certain expenses are denominated in NIS. Our general and administrative expenses, excluding stock-based compensation, share-based payments and depreciation, for the three months ended March 31, 2026 were $2,002 compared to $2,304 for the three months ended March 31, 2025, a decrease of $302.

Our general and administrative expenses consist mainly of employees' salaries and related overhead costs, stock-based compensation, insurance costs, legal and accounting fees, acquisition-related costs, and expenses related to investor relations.

*Financial Expenses (Income), net*

Our financial expenses (income), net for the three months ended March 31, 2026 were $883, compared to $(204) for the three months ended March 31, 2025. The decrease in our financial income was mainly due to financial income resulting from the revaluation of pre-funded warrants in the first quarter of 2025 which were fully exercised in February 2026.

Financial income, net primarily consists of credit facility interest expense, interest income from cash balances, revaluation of warrants and pre-funded warrants, bank charges, lease liability and foreign currency translation differences.

*Income tax*

Income tax expenses were $57 for the three months ended March 31, 2026, compared to $22 for the three months ended March 31, 2025. Income tax expenses for the three months ended March 31, 2026 were primarily comprised of sales tax and state tax.

*Net loss*

Net loss decreased by $978, or 10.6%, to $8,249 for the three months ended March 31, 2026, compared to a net loss of $9,227 for the three months ended March 31, 2025. The decrease in net loss was mainly due to decrease in operating expenses.

The factors described above resulted in net loss attributable to common stockholders for the three months ended March 31, 2026 of $8,249, compared to net loss attributable to common stockholders of $14,066 for the three months ended March 31, 2025.

#### Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented in accordance with U.S. GAAP within this Quarterly Report on Form 10-Q, management provides certain non-GAAP financial measures ("NGFM") of the Company's financial results, including such amounts captioned "Non-GAAP Adjusted Loss," as presented herein below. The NGFM measures captioned "Non-GAAP Adjusted Loss" are not recognized terms under U.S. GAAP, and as such, they are not a substitute for, considered superior to, considered separately from, nor as an alternative to, U.S. GAAP and/or the most directly comparable U.S. GAAP financial measures.

Such NGFM are presented with the intent of providing greater transparency of information used by us in our financial performance analysis and operational decision-making. We believe these NGFM provide meaningful information to assist investors, shareholders, and other readers of our unaudited condensed consolidated financial statements in making comparisons to our historical financial results, and analyzing the underlying financial results of our operations. We believe the NGFM provide useful information by isolating certain expenses, gains, and losses which are not necessarily indicative of our operating financial results and business outlook.

[**Table of Contents**](#TOC)

A reconciliation to the most directly comparable U.S. GAAP measure to NGFM, as discussed above, is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** |
|  | **2026** | **2025** | **$ Change** |
| **Net Loss Reconciliation** |  |  |  |
| Net loss - as reported | $(8249) | $(9227) | $978 |
| Adjustments |  |  |  |
| &nbsp;&nbsp;Depreciation and impairment expense | 61 | 94 | (33) |
| &nbsp;&nbsp;Amortization of acquired intangible assets | 463 | 1162 | (699) |
| &nbsp;&nbsp;Financial (income) expenses, net | 883 | (204) | 1087 |
| &nbsp;&nbsp;Income tax | 57 | 22 | 35 |
| &nbsp;&nbsp;Stock-based compensation expenses | 1441 | 2342 | (901) |
| Non-GAAP adjusted loss | $(5344) | $(5811) | $467 |

---

#### Liquidity and Capital Resources
As of March 31, 2026, we had approximately $14,977 in cash and cash equivalents and $5,035 in short term deposits compared to $21,803 and $4,214 on December 31, 2025.

We have experienced cumulative losses of $460,327 since inception (August 11, 2011) through March 31, 2026, and have stockholders' equity of $62,380 as of March 31, 2026. In addition, we have not completed our efforts to establish a stable recurring source of revenues sufficient to cover our operating costs and expect to continue to generate losses for the foreseeable future.

Since inception, we have financed our operations primarily through private placements and public offerings of our Common Stock and warrants to purchase shares of our Common Stock, receiving aggregate net proceeds totaling $307,133 through March 31, 2026, and a credit facility, net in the amount of $25,795 as of March 31, 2026.

On April 30, 2025, we entered into a Credit Agreement (the "Credit Agreement"), by and among us as borrower, the financial institutions party thereto from time to time as lenders, and Callodine Commercial Finance, LLC (in its capacity as agent for all lenders, "Agent", and collectively with other lenders, "Lenders" and each a "Lender"). Under the terms of the Credit Agreement, each Lender agreed to make a multi-draw term loan to us of up to $50,000 (each a "Term Loan") in which we borrowed $32,500 at the time of closing on April 30, 2025 (the "Callodine Loan Facility"). The Callodine Loan Facility has a five-year term maturing in April 2030, with principal repayments not due until May 2028. The outstanding principal balance bears interest at SOFR plus 7.75%. In addition, we may draw up to an additional $17,500 subject to certain conditions. As of March 31, 2026, the outstanding balance under the Callodine Loan Facility was $30,931.

All obligations under the Credit Agreement are guaranteed by our subsidiaries (each a "Grantor"). All obligations under the Credit Agreement, and the guarantees of those obligations, are secured by substantially all of our and the Grantors' assets. In the event of a default set forth in the Credit Agreement, the Agent may apply all or any part of the proceeds as collateral to the payment of the obligations in the order and priority as determined by the Agent in its sole discretion.

The outstanding principal balance under the loan shall bear interest at a per annum rate of interest equal to (i) the Term SOFR Rate (as defined in the Credit Agreement) plus (ii) seven and three-quarters of one percent (7.75%). Upon maturity and/or upon an event of default (or upon any acceleration), interest shall automatically accrue without notice to us at a rate per annum equal to the lesser of (i) three percent (3%) over the Contract Rate (as defined in the Credit Agreement), or (ii) the maximum rate of interest permitted to be charged by applicable laws or regulations until paid. We will pay certain fees with respect to the Term Loan, including a closing fee, an exit fee, and an agent fee. Voluntary prepayments of the Term Loan prior to the third anniversary of the closing are also subject to certain pre-payment penalties.

[**Table of Contents**](#TOC)

The Credit Agreement contains customary events of default, including with respect to nonpayment of principal, interest, fees or other amounts; material inaccuracy of a representation or warranty; failure to perform or observe covenants; bankruptcy and insolvency events; material monetary judgment defaults; impairment of any material definitive loan documentation; other material adverse effects; key person events and change of control.

The Credit Agreement also contains a number of customary representations, warranties and covenants that, among other things, will limit or restrict our ability and the ability of our subsidiaries to (subject to certain qualifications and exceptions): create liens and encumbrances; incur additional indebtedness; merge, dissolve, liquidate or consolidate; make acquisitions, investments, advances or loans; dispose of or transfer assets; pay dividends or make other payments in respect of their capital stock; amend certain material documents; redeem or repurchase certain debt; engage in certain transactions with affiliates; and enter into certain restrictive agreements.

In connection with the funding of the closing amount, we agreed to issue for each Lender a warrant to purchase 105,707 shares of our Common Stock, with an exercise price of $16.56, which shall have a term of seven years from the issuance date. In addition, up to $2,500 of the loaned amount can be converted into shares of our Common Stock at a price of $19.87 per share.

On August 15, 2025, the Company did not meet one of the financial covenants under the Credit Agreement. Upon an Event of Default (as defined in the Credit Agreement) under the Credit Agreement, interest shall accrue to at a rate per annum equal to the lesser of (i) three percent (3%) over the Contract Rate (as defined in the Credit Agreement), or (ii) the maximum rate of interest permitted to be charged by applicable laws or regulations, until paid. The Company notified Callodine of its intention to utilize an Equity Cure (as defined in the Credit Agreement) to address the event of default. Callodine waived the event of default, subject to the successful implementation of an Equity Cure no later than October 3, 2025.

On November 5, 2025, we entered into an Amendment to the Credit Agreement with the Lenders. Among other things, the amendment (i) resets financial covenants and waives financial-covenant testing for the second and third quarters of 2025; (ii) replaces the minimum cash covenant with a $10,000 minimum consolidated unencumbered liquid assets covenant; (iii) adds monthly 13-week cash-flow reporting when liquidity is below certain amount (subject to an EBITDA exception); (iv) clarifies that Tranche B is uncommitted and at lender discretion; and (v) increases the exit fee by $150 (waived if a change-of-control prepayment fee is triggered).

In connection therewith, the Company repriced the Warrant to purchase up to 105,707 shares of Common Stock issued to the lenders on April 30, 2025, at an exercise price $16.56 per share, to permit an amendment to the exercise price of such Warrants to $15.35. In addition, conversion right of the lender in the amount of $2,500 was amended to a conversion price of $15.35 per share.

On December 16, 2024, we and certain purchasers that were holders of our Series B and C Preferred Stock executed lock up agreements (the "Lock Up Agreement"), pursuant to which we agreed to issue, subject to stockholder approval, up to forty percent (40%) of the shares of Common Stock conversion shares of the preferred stock held by such purchaser, including dividend shares of Common Stock due upon conversion of these shares into shares of Common Stock, over the course of twelve (12) months (the "Additional Shares"). Each holder shall be entitled to receive 10% of the Additional Shares for each three (3) month period each holder agrees not to transfer or otherwise sell (subject to certain limitations) the shares of Common Stock issuable upon conversion of the Series B Preferred Stock and Series C Preferred Stock and the dividend shares of Common Stock due upon conversion. Between May 23, 2025 and May 28, 2025, the Company and holders that previously entered into Lock-Up Agreements, entered into an Amended and Restated Lock-Up Agreement (the "A&R Lock-Up Agreement") pursuant to which the holders agreed to extend the restrictive period previously provided in the Lock-Up Agreements until February 21, 2026 (the "Lock Up Period") for the right to receive an additional 10% of the Common Stock underlying the Series B Preferred Stock and the Series C Preferred Stock held by the holders. On October 20, 2025, we and holders that previously entered into the Lock-Up Agreement and the A&R Lock-Up Agreement entered into a Second Amended and Restated Lock-Up Agreement (the "Second A&R Lock-Up Agreement") pursuant to which the Lock-Up Period shall automatically terminate, and all share consideration shall be accelerated and immediately be issued by us in full (to the extent not already issued) upon (A) any merger or consolidation

[**Table of Contents**](#TOC)

of our with or into another individual, entity, corporation, partnership, association, limited liability company, limited liability partnership, joint-stock company, trust or unincorporated organization, (B) any sale of all or substantially all of our assets in one transaction or a series of related transactions, or (C) any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property.

On March 30, 2026, we entered into the Sales Agreement with A.G.P./Alliance Global Partners, pursuant to which we may offer and sell, from time to time, up to an aggregate of $20.0 million of shares of our common stock under the ATM Program. Sales of shares under the Sales Agreement, if any, may be made by any method permitted by law that is deemed to be an "at the market offering" under Rule 415(a)(4) under the Securities Act, or in negotiated transactions or as principal pursuant to a separate terms agreement. We have no obligation to sell any shares under the ATM Program and may suspend offers thereunder or terminate the Sales Agreement at any time, subject to its terms.

We intend to use any net proceeds from the ATM Program for commercial, sales and marketing activities, research and development, potential mergers and acquisitions, repayment of outstanding indebtedness and related interest under the Callodine Loan Facility, and for general corporate and working capital purposes.

The Sales Agreement provides that the Agent is entitled to a commission of 3.0% of the gross sales price of shares sold under the ATM Program. We have also agreed to reimburse certain reasonable and documented expenses of the Agent, including legal fees and other customary expenses, subject to specified caps. The Sales Agreement contains customary representations, warranties, covenants, indemnification obligations and termination provisions.

As of March 31, 2026, no shares had been sold under the ATM Program. Subsequent to March 31, 2026 and through the date of this Quarterly Report on Form 10-Q, we sold an aggregate of 7,252 shares under the ATM Program for gross proceeds of approximately $54 and net proceeds of approximately $53, after deducting commissions and offering expenses.

There are no assurances that we will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of our product offerings.

As such, we have a significant present need for capital. If we are unable to scale up our commercial launch of our products or meet our commercial sales targets (or if we are unable to generate any revenue at all), and if we are unable to obtain additional capital resources in the near term, we may be unable to continue activities absent material alterations in our business plans and our business might fail.

Based on the Company's updated cash flow projections as of the date of these financial statements, and the conditions noted above, we believe that our current cash on hand will not be sufficient to fund our projected operating requirements for a period of one year from the issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern.

Additionally, readers are advised that available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected.

#### Cash Flows
The following table sets forth selected cash flow information for the periods indicated:

---

| | | |
|:---|:---|:---|
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
|  | **$** | **$** |
| Cash used in operating activities: | (6025) | (6673) |
| Cash used in investing activities: | (826) | (31) |
| Cash provided by financing activities: |  | 6815 |
|  | (6851) | 111 |

---

[**Table of Contents**](#TOC)

*Net cash used in operating activities*

Net cash used in operating activities was $6,025 for the three months ended March 31, 2026, a decrease of 9.7% compared to $6,673 used in operations for three months ended March 31, 2025. Cash used in operations decreased mainly due to the decrease in our operating expenses.

*Net cash used in investing activities*

Net cash used in investing activities was $826 for the three months ended March 31, 2026, compared to $31 net cash used in investing activities during the same period in 2025. The increase is due to investments in short term bank deposit, compared to the same period in 2025.

*Net cash provided from financing activities*

There were no financing activities during the three months ended March 31, 2026, compared to $6,815 net cash derived from financing activities during the same period in 2025. The 2025 amount was mainly attributable to proceeds from the issuance of shares of preferred stock.

#### Item 4. Controls and Procedures.
*Evaluation of Disclosure Controls and Procedures*

As of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer (the "Certifying Officers"), conducted evaluations of our disclosure controls and procedures. As defined under Sections 13a–15(e) and 15d–15(e) of the Securities Exchange Act of 1934, as amended, (the "Exchange Act", the term "disclosure controls and procedures" means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including the Certifying Officers, to allow timely decisions regarding required disclosures.

Based on their evaluation, the Certifying Officers concluded that, as of March 31, 2026, our disclosure controls and procedures were designed at a reasonable assurance level and were therefore effective.

*Changes in Internal Control over Financial Reporting*

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

*Limitations on the Effectiveness of Internal Controls*

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

[**Table of Contents**](#TOC)

#### PART II - OTHER INFORMATION

#### Item 1A. Risk Factors.
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, which could materially affect our business, financial condition, or future results.

There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, except as noted below.

***We believe our current cash on hand will not be sufficient to fund our projected operating requirements for a period of one year from the issuance of these interim financial statements. This raises substantial doubt about our ability to continue as a going concern.***

We believe that our current cash on hand will not be sufficient to fund our projected operating requirements for a period of one year from the issuance of our interim financial statements. This raises substantial doubt about our ability to continue as a going concern and could materially limit our ability to raise additional funds through the issuance of equity or debt securities or otherwise. If we cannot continue as a going concern, our investors may lose their entire investment in our securities. Until we can generate significant revenues, we expect to satisfy our future cash needs through equity or debt financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate product development plans commercialization, sales and marketing, or other strategic initiatives.

[**Table of Contents**](#TOC)

#### Item 6. Exhibits.

---

| | |
|:---|:---|
| **No.** | **Description of** <br>**Exhibit**  |
| 10.1 | [Sales Agreement between the Company and A.G.P./Alliance Global Partners, dated March 30, 2026 (incorporated by reference to Exhibit 10.1 filed with the Company's Current Report on Form 8-K filed on March 30, 2026).](https://www.sec.gov/Archives/edgar/data/1533998/000110465926036834/tm2610107d1_ex10-1.htm) |
| 31.1\* | [Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).](drio-20260331xex31d1.htm) |
| 31.2\* | [Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).](drio-20260331xex31d2.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.](drio-20260331xex32d1.htm) |
| 32.2\*\* | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.](drio-20260331xex32d2.htm) |
| 101.1\* | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Statements of Changes in Stockholders' Equity, (iv) Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail. |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). |

---

\*Filed herewith.

\*\*Furnished herewith.

[**Table of Contents**](#TOC)

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: May 13, 2026 |  | **DarioHealth Corp.** | **DarioHealth Corp.** |
|  | By: | /s/ Erez Raphael | /s/ Erez Raphael |
|  |  | Name: | Erez Raphael |
|  |  | Title: | Chief Executive Officer (Principal Executive Officer) |
|  | By: | /s/ Chen Franco-Yehuda | /s/ Chen Franco-Yehuda |
|  |  | Name: | Chen Franco-Yehuda |
|  |  | Title: | Chief Financial Officer, Secretary and Treasurer (Principal Financial Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED**

I, Erez Raphael, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DarioHealth Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2026

---

| |
|:---|
| /s/ Erez Raphael |
| Erez Raphael |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED**

I, Chen Franco-Yehuda, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DarioHealth Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2026

---

| |
|:---|
| /s/ Chen Franco-Yehuda |
| Chen Franco-Yehuda |
| Chief Financial Officer, Secretary and Treasurer |
| (Principal Financial Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**DARIOHEALTH CORP.**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the quarterly report of DarioHealth Corp., or the Company, on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Erez Raphael, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Erez Raphael |
| Erez Raphael |
| Chief Executive Officer |
| (Principal Executive Officer) |
| May 13, 2026 |

---

------

## Exhibit 32.2

**Exhibit 32.2**

**DARIOHEALTH CORP.**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the quarterly report of DarioHealth Corp., or the Company, on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Chen Franco-Yehuda, Chief Financial Officer, Secretary and Treasurer, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Chen Franco-Yehuda |
| Chen Franco-Yehuda |
| Chief Financial Officer, Secretary and Treasurer |
| (Principal Financial Officer) |
| May 13, 2026 |

---

------